(Reuters) – Novo Holdings has completed its $16.5 billion takeover of Catalent, the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled.
Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, which makes the blockbuster GLP-1 injectable weight-loss drug Wegovy.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Maju Samuel)
Comments